- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| VINCERX PHARMA Aktie jetzt für 0€ handeln | |||||
| 12.11. | Vincerx Pharma Inc reports results for the quarter ended September 30 - Earnings Summary | 3 | Reuters | ||
| 12.11. | Vincerx Pharma GAAP EPS of -$0.17 | 1 | Seeking Alpha | ||
| 12.11. | Vincerx Pharma, Inc.: Vincerx Pharma Reports Third Quarter 2024 Financial Results | 69 | GlobeNewswire (Europe) | Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase... ► Artikel lesen | |
| 12.11. | Vincerx Pharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.11. | Vincerx Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.10. | Penny Stock Cancer-Focused Vincerx Pharma Seeks Development Partner For 2 Early-Stage Blood Cancer Candidates | 17 | Benzinga.com | ||
| 08.10. | Vincerx stock tumbles 20% on corporate updates | 10 | Seeking Alpha | ||
| 08.10. | Leerink senkt Kursziel für Vincerx Pharma nach Pipeline-Update | 10 | Investing.com Deutsch | ||
| 08.10. | Leerink cuts Vincerx Pharma stock target on pipeline update | 3 | Investing.com | ||
| 08.10. | Vincerx Reports Positive Initial Clinical Data From VIP943 Phase 1 Dose-Escalation Study | 5 | RTTNews | ||
| 07.10. | Vincerx Pharma, Inc.: Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates | 91 | GlobeNewswire (Europe) | VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx... ► Artikel lesen | |
| 16.08. | Vincerx Pharma, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.08. | Vincerx Pharma GAAP EPS of -$0.05 | 3 | Seeking Alpha | ||
| 08.08. | Vincerx Pharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | Vincerx Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Vincerx Pharma, Inc.: Vincerx Pharma Reports Second Quarter 2024 Financial Results | 80 | GlobeNewswire (Europe) | Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMDC) VIP236, with data expected... ► Artikel lesen | |
| 21.06. | Vincerx Pharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.05. | Vincerx Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 14.05. | Vincerx Pharma, Inc.: Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update | 187 | GlobeNewswire (Europe) | Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate... ► Artikel lesen | |
| 08.04. | Vincerx Pharma, Inc.: Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024 | 135 | GlobeNewswire (Europe) | VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ASTRIA THERAPEUTICS | 8,950 | -3,24 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 22,350 | 0,00 % | Why Rocket Lab Stock Rocketed Again on Friday | ||
| BOIRON | 27,400 | -7,12 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| HARROW | 42,940 | -2,16 % | Harrow subsidiary wins $34.9 million in trademark case | ||
| MEDICINOVA | 1,700 | 0,00 % | MediciNova, Inc.: MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders | LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 1,840 | +4,55 % | ESSA Pharma: NBC-Anlegerclub feiert schnelle +23% Rendite! | Der No Brainer Club (NBC) hat erneut sein Gespür für unterbewertete Biotech-Perlen unter Beweis gestellt. Mit ESSA Pharma konnten Mitglieder in diesem fulminanten Biotech-Herbst innerhalb weniger Tage... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,550 | +0,11 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Anaphylm (epinephrine) Sublingual Film pre-NDA meeting scheduled for fourth quarter 2024AQST-108 (epinephrine) Topical Gel pre-IND meeting scheduled for fourth quarter 2024Libervant® (diazepam) Buccal... ► Artikel lesen | |
| SHINECO | 2,710 | +3,83 % | Shineco, Inc.: Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement | BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today... ► Artikel lesen | |
| LYRA THERAPEUTICS | 0,186 | +2,36 % | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| CYANOTECH | 0,260 | 0,00 % | Cyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025 | KAILUA KONA, Hawaii--(BUSINESS WIRE)--Cyanotech Corporation (OTCQB: CYAN), a world leader in microalgae-based, high-value nutrition and health dietary supplement products, announced financial results... ► Artikel lesen | |
| REVIVA PHARMACEUTICALS | 1,180 | -4,84 % | Reviva Pharmaceuticals: Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial - - Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine's improvement on negative... ► Artikel lesen | |
| CUMBERLAND PHARMACEUTICALS | 1,060 | -1,85 % | Cumberland Pharmaceuticals Inc.: Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update | - New Real World Study of 150,000 Patients Favors Caldolor over ketorolac -
- DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations... ► Artikel lesen | |
| OMNIAB | 3,925 | +1,95 % | OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights | EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program... ► Artikel lesen | |
| BAYER | 19,802 | +1,46 % | Rückschlag für Bayer: Wie reagiert der Konzern? | Bayer verzeichnet im dritten Quartal 2024 tiefrote Zahlen: Ein Nettoverlust von 4,2 Milliarden Euro und ein Umsatzrückgang von 3,6% belasten das Unternehmen. Gleichzeitig belasten Milliardenabschreibungen... ► Artikel lesen | |
| MERCK KGAA | 141,75 | +2,49 % | JPMORGAN stuft MERCK KGAA auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Merck KGaA mit einem Kursziel von 190 Euro auf "Overweight" belassen. Das für 2025 gesteckte Ziel eines operativen Gewinnwachstums... ► Artikel lesen |
Das Unternehmen VINCERX PHARMA INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,261 Euro und damit +2,03 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VINCERX PHARMA INC finden Sie auf Wallstreet Online.
